We sought to determine the diagnostic performance of the new high-sensitivity cardiac troponin T (hs-cTnT) assay for early detection of non-STsegment myocardial infarction (NSTEMI) in patients with acute coronary syndrome.
The Joint European Society of Cardiology/American College of Cardiology/American Heart Association/ World Heart Federation Task Force redefinition of acute myocardial infarction (AMI) 3 is predicated on the detection of an increase or decrease of cardiac troponin (cTn), with at least 1 concentration above the 99th percentile reference value in patients with evidence of myocardial ischemia (1 ) . Blood samples for measurement of cTn are recommended to be drawn at presentation and 6 -9 h later to optimize clinical sensitivity for ruling in AMI. However, the magnitude of such an increase or decrease indicative of AMI in patients with acute coronary syndrome (ACS) has not been determined. In the subset of patients with endstage renal disease a change in the cTn concentration of Ն20% in the 6 -9 h after presentation has been recommended because it represents a significant (3 SD) change in cTn on the basis of a 5%-7% analytical CV (2 ) .
Because of improved analytical performance of the new high-sensitive cTnT assay (hs-cTnT), cTnT concentrations within reference intervals can now be measured in most healthy individuals, and imprecision at the 99th percentile reference value concentrations is below 10% CV (3, 4 ) . With a decrease in the diagnostic cutoff by implementation of more sensitive and precise assays, sensitivity is further increased but specificity is decreased owing to detection of more acute, subacute, and chronic cardiac diseases not related to ACS, such as heart failure and cardiomyopathies (5) (6) (7) (8) . To ensure clinical specificity for MI diagnosis, adherence to the criteria of the universal MI definition is paramount because there is an emerging need for serial testing to distinguish an acute from a chronic elevation of hscTnT (9 ) .
The purpose of this study was to determine the diagnostic performance of the new hs-cTnT assay by using baseline concentrations Ն99th percentile and ␦ change in subsequent blood draws within 3 and 6 h for earlier detection of evolving NSTEMI in patients presenting with an initially negative result for 4th-generation cTnT.
Materials and Methods
Between May and December 2008, study patients were enrolled who had signs and symptoms suggestive of ACS and who were admitted to the chest pain unit (CPU) of the University of Heidelberg and had a high test probability for non-STE ACS and a cTnT concentration Ͻ0.03 g/L on admission. The likelihood that signs and symptoms represented an ACS secondary to coronary artery disease was estimated according to the criteria proposed by Braunwald et al. (10 ) . The CPU of Heidelberg is a specialized emergency department of internal medicine and provides first medical care and diagnostic work-ups to patients with cardiovascular emergencies, particularly those with acute chest pain. In 2007 almost 7000 patients were admitted to the CPU, of whom one-third presented with thoracic pain. Noncardiac chest pain was diagnosed in one-third of these patients and ACS in two-thirds (20% STEMI, 40% NSTEMI, and 40% unstable angina).
All patients underwent a 12-lead electrocardiogram (ECG) recording on admission and a second 12-lead ECG after 6 h. Blood samples were collected on admission, at 60-min intervals within the initial 6 h after admission, and the next morning unless venipuncture was not feasible for technical reasons or the patient refused the blood draw.
We excluded patients who underwent immediate or early percutaneous coronary intervention (PCI) before a final diagnosis of unstable angina or NSTEMI could be made, because PCI may induce postinterventional infarction or aggravate ongoing myocardial necrosis. We also excluded patients with significant kidney dysfunction defined as an estimated glomerular filtration rate below 60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 )
Ϫ1
. MI was diagnosed according to the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of MI guidelines (1 ) . Accordingly, diagnosis of NSTEMI required the detection of an increasing or decreasing pattern of the fourthgeneration cTnT above the 10% CV (Ն0.03 g/L) with at least 1 of the following symptoms: ischemia, new ST-T changes on ECG, development of Q waves on ECG, and imaging evidence of new loss of viable myocardium. Patients with normal cTnT on presentation and cTnT Ն0.03 g/L in any subsequent blood draws were classified as evolving NSTEMI. Diagnosis of unstable angina was made in the presence of cTnT concentrations Ͻ0.03 g/L on presentation and during subsequent samples within 24 h after the index event, together with typical angina at rest, a deterioration of previously stable angina, coronary angiogram showing stenosis of 50% or more of the vessel diameter with or without the need for subsequent coronary intervention, a positive result on a cardiac exercise test, or a high clinical probability based on history of coronary artery disease, prior PCI, or coronary artery bypass graft.
To classify the angiographic appearance of the culprit vessel on coronary angiogram, we used the Ambrose classification (11 ) . This classification categorizes lesions into 4 types: (a) concentric (symmetric and smooth narrowing), (b) type I eccentric (asymmetric stenosis with smooth borders and a broad neck), (c) type II eccentric (asymmetric stenosis in the form of a convex intraluminal obstruction with a narrow base due to Ն1 overhanging edges or extremely irregular or scalloped borders, or both), and (d) multiple irregularities (Ն3 serial and closely spaced severe obstructions or severe diffuse irregularities). In addition we assessed the presence of an intraluminal filling defect or haziness suggestive of thrombus. In patients with unstable angina or NSTEMI, immediate, early, or deferred coronary angiography and PCI were performed at the discretion of the attending cardiologist. The protocol was approved by the ethics committee of the University of Heidelberg and all patients gave informed consent.
After collection, blood samples were centrifuged immediately and serum stored at Ϫ80°C until analysis. The laboratory staff responsible for measurements was blinded to patient data. All laboratory measurements were performed in the research laboratory of Roche Diagnostics in Penzberg, Germany, and we used the latest precommercial version of the new hs-cTnT assay, which is identical to the commercially available hscTnT assay (Klaus Hallermayer, personal communication, August 2009). The lower detection limit of hs-cTnT is 3 ng/L (0.003 g/L). As described previously, the interassay CV was 8% at 10 ng/L and 2.5% at 100 ng/L. The intraassay CV was 5% at 10 ng/L and 1% at 100 ng/L (3 ). Preliminary data demonstrated detectable concentrations in 2 healthy reference populations with a 99th percentile concentration of 13.25 ng/L.
We measured cTnT using a commercial 1-step EIA based on electrochemiluminescence technology (fourth-generation TnT, Elecsys 2010, Roche). The lower detection limit of this assay is 0.01 g/L, with a recommended diagnostic threshold of 0.03 g/L. At this concentration, cTnT concentrations can be measured with a CV Ͻ10% (4 ). Several sets of criteria were evaluated, including cTnT and hs-cTnT concentrations Ն99th percentile reference values (Ն0.01 g/L and Ն14 ng/L, respectively), as well as a ␦ change Ն20%, and ՆROC-optimized changes.
Results
During 6 months a total of 863 patients with ACS were admitted. Online Fig. 1 (in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol56/issue4) displays how the study population was extracted from the consecutive patient population admitted to the CPU (Fig.  1 ). Briefly, we excluded patients with STEMI (n ϭ 263) and patients with NSTEMI (n ϭ 268) on presentation. In addition we excluded patients who underwent immediate or early coronary angiography with or without PCI (n ϭ 45), those with renal dysfunction (n ϭ 12), those who refused serial blood testing (n ϭ 15), and those in whom venipuncture was not feasible (n ϭ 2). Thus, 57 patients with retrospectively confirmed unstable angina and evolving NSTEMI comprised the study population. Based on the 0.03 g/L decision cutoff with use of the fourth-generation cTnT assay as the reference, evolving NSTEMI was identified in 26 patients and unstable angina in 31 patients. A mean (SD) of 4.5 (2.3) samples per patient (median 5 samples (25th;75th percentile 2;6) were obtained within the initial 6 h after admission.
Baseline characteristics of the study population are displayed in Table 1 . Those patients with evolving NSTEMI had more frequent unstable angina at rest within the last 48 h (Braunwald class III), significantly shorter time delays from onset of symptoms to hospital admission, more severe coronary artery disease, and more frequently underwent PCI and coronary stenting than patients with unstable angina. Analysis of culprit lesion morphology according to the Ambrose classification (11 ) demonstrated a trend to more type II eccentric lesions (P ϭ 0.059), more lesions with intraluminal filling defects or haziness suggestive of intracoronary thrombus (P ϭ 0.044), and fewer concentric lesions (P ϭ 0.013) among patients with evolving NSTEMI compared with those with unstable angina. In a subanalysis regarding the morphology of the culprit lesion and ␦ change among patients with unstable angina, we found that concentric lesions were almost entirely restricted to cases with a ␦ change of ϩ21% to ϩ30% (n ϭ 5), Ϫ20% to ϩ 20% (n ϭ 7), ϾϪ20% (n ϭ 1), and ϩ31% to ϩ117% (n ϭ 1). Intraluminal filling defects or haziness were associated with a ␦ change Ն118% (n ϭ 2), ϩ31% to 117% (n ϭ 1), and ϾϪ20% (n ϭ 1), suggesting that less complex lesions are associated with smaller changes of hs-cTnT.
PERFORMANCE OF BASELINE cTnT AND hs-cTnT
Baseline hs-cTnT concentrations were significantly higher in patients with evolving NSTEMI compared with those with unstable angina [28.6 (42.8) ng/L vs 9.4 (11.7) ng/L, P Ͻ 0.001]. On admission, a cTnT concentration Ն0.01 g/L obtained by using the fourthgeneration assay was seen in 3 of 31 patients with unstable angina and in 2 of 26 patients with evolving NSTEMI.
A baseline hs-cTnT concentration Ն14 ng/L obtained by using the hs-cTnT assay was seen in 7 of 31 patients with unstable angina and in 16 of 26 patients with evolving NSTEMI. Corresponding sensitivities, specificities, and positive and negative predictive values are displayed in Table 2 . A significant difference between groups was found for a ␦ change Ն118% (P ϭ 0.00046). Absolute numbers are given within the stacked columns. For stacked bars, grey color indicates delta change Նϩ118%, white color ϩ31% to ϩ117%; vertical lines ϩ21% to ϩ30%, diagonal lines Ϫ20% to ϩ20%, and horizontal lines ՆϪ20%.
PERFORMANCE OF SERIAL MEASUREMENTS
those with unstable angina. The distribution of the ␦ change in patients classified as having unstable angina and those classified as having evolving NSTEMI are displayed in a stacked column plot showing that significantly more patients with evolving NSTEMI had a ␦ change Ն118% (Fig. 1) . Accordingly, the maximum ␦ changes of hs-cTnT in any subsequent sample were significantly higher in patients with evolving NSTEMI (Fig. 2 ) compared with those with unstable angina (Fig. 3) within 3 0.925) and Ն243% within 6 h (area under the ROC curve 0.911, 95% CI 0.782-0.976) to differentiate unstable angina from evolving NSTEMI (online Supplemental Fig. 2 ). hs-cTnT concentrations Ն14 ng/L were seen in 16 of 26 patients with evolving NSTEMI on presentation, in 22 of 26 patients within 3 h, and in all patients within 6 h. In patients with unstable angina an hs-cTnT Ն14 ng/L was observed in 7 of 31 patients on presentation, in 8 of 31 patients within 3 h, and in 9 of 31 patients within 6 h. Likewise, in patients with evolving NSTEMI a cTnT concentration Ն0.01 g/L was seen in 2 of 26 patients on presentation, 13 of 26 patients within 3 h, and all patients within 6 h. In patients with unstable angina cTnT concentrations Ն0.01 g/L were noted in 3 of 31 patients on presentation and 4 of 31 patients within 3 and 6 h.
In those 9 cases that had to be reclassified as NSTEMI owing to an hs-TnT concentration above the 99th percentile, there were no significant differences regarding rates of Braunwald ՆIIA angina (6 of 9 cases vs 24 of 31 cases, P ϭ 0.82) or a history of significant coronary artery disease (8 of 9 cases vs 20 of 31 cases, P ϭ 0.32) compared with patients with a diagnosis of unstable angina (n ϭ 31). Furthermore, there was a nonsignificant trend for higher rates of impaired left ventricular function (8 of 9 cases vs 17 of 31 cases, P ϭ 0.11), and significantly higher rates of early PCI (8 of 9 vs 12 of 31, P ϭ 0.02). There was no difference regarding the angiographic appearance of the culprit lesion (type I eccentric, n ϭ 3; type II eccentric, n ϭ 3; multiple irregularities, n ϭ 2; intraluminal thrombus, n ϭ 1) between those patients with an hs-cTnT concentration above or below the 99th percentile value.
Use of the 99th percentile value alone or use of the 99th percentile cutoff in association with a characteristic rise and fall had an important effect on the number of patients in whom MI was diagnosed. Thus, use of the 99th percentile cutoff alone identified all patients with a final diagnosis of NSTEMI. Among patients with unstable angina, hs-cTnT for which we used the 99th percentile cutoff identified 9 additional patients whose disease would qualify for a diagnosis of NSTEMI, whereas the fourth-generation cTnT using the 99th percentile cutoff (Ն0.01 g/L) identified only 4 additional patients with a diagnosis of NSTEMI. If hs-cTnT measurements at the 99th percentile value were considered together with a ␦ change Ն20% or ՆROC optimized ␦ change in any subsequent blood sample within 6 h, the number of diagnosed MI was reduced from 9 to 4 cases using ␦ change Ն20%, and use of the ROC-optimized ␦ change further reduced this number to zero. Thus, the implementation of ROC-optimized ␦ change Ͼ117% within 3 h or Ն243% within 6 h yielded a specificity of 100% at a sensitivity between 69% and 76%. Corresponding sensitivities, specificities, and positive and negative predictive values are displayed in Table 3 .
Discussion
We evaluated the diagnostic performance of the new more sensitive and precise hs-cTnT assay at the 99th percentile cutoff compared with the diagnostic performance of the fourth-generation cTnT assay at the 99th percentile cutoff (0.01 g/L) for the prediction of evolving NSTEMI. For this purpose the sensitivities and specificities of the baseline and early follow-up samples were calculated and compared with the cTnT standard at the recommended cutoff of 0.03 g/L, which corresponds to the concentration at which the assay imprecision is below 10% CV. In addition, we tested the usefulness of the ␦ change of the follow-up sample within 3 and 6 h from baseline.
We found that the 99th percentile cutoff used with the hs-cTnT assay allowed an earlier diagnosis of evolving NSTEMI compared with the cTnT standard at the 0.03 g/L cutoff concentration. hs-cTnT concentrations Ն99th percentile were already present on admission in 61.5% of patients, and increased gradually to 100% within 6 h. Compared with the fourthgeneration cTnT assay at the 99th percentile, the hscTnT assay on initial measurement identified more patients with myocardial necrosis (61.5% vs 7.7%, P Ͻ 0.0001).
Consistent findings regarding earlier detection of myocardial necrosis have already been reported with other ultrasensitive cTnI assays (12, 13 ) . More recently, the superior performance of high-sensitivity troponin T and I assays for earlier detection of MI compared with the less sensitive fourth-generation cTnT assay was confirmed in 2 larger trials comparing the cTnT standard with an ultrasensitive troponin I assay (14 ) or 3 hs-cTnI assays and the new hs-cTnT assay (15 ) .
In a multicenter trial, Keller et al. (14 ) studied the performance of an hs-cTnI assay compared with the standard cTnT assay perfomed on admission and 3 h and 6 h after admission in 1818 consecutive patients with suspected AMI. The authors reported that a single The baseline concentration of hs-cTnT increases from a median of 4.3 ng/L (25th;75th percentile 0.99;9.61) to 2.9 ng/L (25th;75th percentile 0.97;13.06) (n ϭ 31, P ϭ 0.87).
hs-cTnT Predicting Evolving NSTEMI
sensitive troponin I concentration result Ն0.04 g/L had a negative predictive value of 84.1% and a positive predictive value of 86.7% in patients presenting within 3 h after chest-pain onset. Reichlin et al. (15 ) studied 718 consecutive patients who presented with symptoms suggestive of AMI and found superior performance of all 4 hs-cTn assays for earlier detection of MI compared with the standard assay. In their analysis, an hs-cTnT concentration Ն99th percentile value on presentation allowed the diagnosis of NSTEMI with a sensitivity of 95% and a specificity of 80%. In our analysis, sensitivity and specificity of the baseline sample were lower but increased to 100% and 76.7%, respectively, after a subsequent sample within 3 h. The reasons for these somewhat divergent results are not fully understood but may be explained by longer time delays from onset of symptoms to admission in the cohort of Reichlin et al. (presentation within 3 h only in 28.2% vs 50% in our study cohort). In our study, the higher analytical sensitivity of hs-cTnT also resulted in a larger, albeit not significant, rate of MI diagnosis among those cases classified as unstable angina (22.6% vs 9.7%, P ϭ 0.30) compared with the fourth-generation cTnT assay at the 99th percentile cutoff, thereby-and not unexpectedlylowering the diagnostic specificity. Adoption of the European Society of Cardiology/American College of Cardiology redefinition of MI with the use of the 99th percentile value as cutoff will ultimately increase the frequency of AMI diagnosis (16 ) .
A strategy that has been advocated to improve clinical specificity is to implement the rise and fall of cTn for diagnosis of MI (1, 9, 17 ) . However, the magnitude of such a ␦ change has not yet been defined. In our small study, an ROC-optimized ␦ change Ͼ117% within 3 h or Ն243% within 6 h yielded a specificity of 100% at a sensitivity between 69% and 76%. Conversely, the performance of cTnT at the 99th percentile cutoff in combination with a ␦ change Ն20% within 3 h was limited by a disappointingly low specificity, whereas performance of serial measurements beyond the initial 3 h showed a comparable performance between cTnT and hs-cTnT, using either a ␦ change Ն20% or ՆROC-optimized value. Previously Apple et al. tested the utility of percentage changes in cTnI of Ն10, Ն20, and Ն30%, and reported that Ն30% change in cTnI should be used as the optimal ␦ change in addition to either the baseline or follow-up concentration. The proposed ␦ change improved both specificity and risk assessment in patients presenting with symptoms of ACS (18 ) .
Other strategies, including the evaluation of an increase of hs-cTnT concentration of more than 3 SD or the use of the short-term reference change value (RCV) were not pursued. Recently it was demonstrated for an ultrasensitive cTnI assay that short-term changes (within 4 h) must exceed a 46% increase or a 32% decrease in serial samples (19 ) . Calculation of the RCV includes the analytical imprecision and the intraindividual variability assessed from serial sampling in a healthy reference population. Because the RCV for the hs-cTnT assay has not yet been determined, we did not attempt to validate the RCV obtained from another higher-sensitivity cTnI assay in our cohort. At follow-up all but 1 of our study patients with evolving NSTEMI had hs-cTnT concentrations Ն99th percentile value with concentrations high enough to warrant high precision (median hs-cTnT 55.3 ng/L; 25th;75th percentile 29.2;72.6). At these concentrations the effect of assay imprecision may be regarded as very low (20 ) . We note the following limitations of our study. We cannot exclude the possibility that patients admitted to a chest pain unit represent a more selected population than patients admitted to an emergency department. Therefore, our data may not be generalized for other settings. Nevertheless, we believe that serial sampling and implementation of a ␦ change criterion will increase clinical specificity and thus the usefulness of hscTnT in less-selected emergency populations. However, forthcoming trials are still needed to validate our observations. Severe kidney dysfunction may increase the prevalence of increased cTnT and to a lesser degree increased cTnI in asymptomatic patients and in those with ACS. To avoid a potential interaction we therefore excluded patients with an estimated glomerular filtration rate below 60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 . Because coronary angioplasty and stenting may result in a postprocedural increase of cTn in cases with cTn within the reference interval and may enhance cTn release in patients with ACS, we deferred analysis of patients who underwent coronary angiography or PCI before the blood sampling protocol was completed. An interesting observation is the association between less complex morphology of the culprit lesion and smaller ␦ change of hs-cTnT among patients with unstable angina. Unfortunately, the number of case patients is too small to allow a meaningful statistical analysis. However, our observation might generate hypotheses for forthcoming studies.
